Friday, November 20, 2015 9:29:37 AM
I've been a buyer of GV this week in the upper 1.60’S and low 1.70's here is what I like.
1) GV Earned .07 this quarter, I think reasonable they can earn .25-.30 going foward, at the current revenue rate. And I don't think it is unreasonable to expect revenue increases sequentially considering my next point.
3) Backlog was a substantially positive for me. I know everyone focuses on the overall backlog down a slight bit sequentially. But that misses the point for the first time in how many quarters can I say the backlog for 12 months is up substantially versus the last 3 month period, in fact it was up over 20% sequentially, this to me was the most exciting part of the pr. Not the earnings, but this.
I was concerned about this trend I do admit until this quarter
Backlog (12 Months)
q3 14 87.4
q4 14 85.3
q1 15 76.8
q2 15 73.0
q3 15 88.5
As one can see this wasn't a pretty picture, before Q3. In fact that number is the highest number I have seen I believe in at the very least recent company history.
3) The other concern is can GV keep margins up. That remains a risk. But it is also could be that those Texas projects were trouble, I know everyone including me got tired of hearing the excuses, but in fairness it was the same project(s) quarter after quarter that was primarily given them the problems, those project have concluded, so I believe that GM will stay relatively healthy from here, as I believe based on what the company said and the quarter the company put up after tell me that is the case, that those projects were simply troubled, but they are behind them.
4) For those that are worried about the sequential drop of revs. I think the 12 month backlog should set aside some of those concerns. More importantly I wonder if q2 seen a boost from the revs finishing those Texas projects, and those revs I'm glad to say goodbye to that is money losing revs, which to me are worse than useless.
Conclusion: I like GV here, I realize it is not without its risks, but I think .25-.30 Going foward conservatively is the number we can look for. Pop a 10 PE on it, and I could see this stock trading in the upper 2's very easily. It may run more, but I want to be conservative.
Admittingly never been a huge supporter of GV, this is the most excited I have been about the stock, for the reason of 12 month backlog up, Money losing project behind them, and stock valuation is too cheap, all of which make me think the stock will go higher in the long run. Time will tell. I will add on weakness. All is just my opinion, and I could always be wrong though.
---All above is just my humble opinion.
And I could always be wrong.
And as always do your own DD.---
http://www.investorshub.com/boards/board.asp?board_id=5316
Recent GV News
- Visionary Holdings Inc. Announcement of Management Change • PR Newswire (US) • 04/23/2024 11:00:00 PM
- Visionary Holdings Inc. Announces Board Change • PR Newswire (US) • 04/04/2024 10:00:00 PM
- Visionary Selects YCM CPA INC as its Independent Registered Public Accounting Firm • PR Newswire (US) • 03/06/2024 11:00:00 PM
- Visionary Announces Board Changes • PR Newswire (US) • 02/08/2024 02:09:00 PM
- Visionary Announces Name Change • PR Newswire (US) • 02/08/2024 01:10:00 PM
- Visionary Education Group Established a MOU with Algoma University • PR Newswire (US) • 01/29/2024 01:00:00 PM
- Visionary Education Group Established a MOU with Algoma University • PR Newswire (US) • 01/18/2024 01:00:00 PM
- GV Announces Successfully Held Global Chinese Capital Establishment Conference • PR Newswire (US) • 01/11/2024 01:00:00 PM
- Visionary Education Technology Holdings Group Inc. Announces Results of 2023 Annual General Meeting and Receipt of NASDAQ Extension Letter • PR Newswire (US) • 12/13/2023 10:00:00 PM
- Algoma University Executives Visited GV Headquarter in Toronto • PR Newswire (US) • 12/12/2023 01:00:00 PM
- Genomic Vision annonce l’ouverture d’une procédure de redressement judiciaire • Business Wire • 11/17/2023 05:00:00 PM
- Genomic Vision Announces the Opening of a Receivership Proceedings • Business Wire • 11/17/2023 05:00:00 PM
- Genomic Vision : Information financière du 3ème trimestre 2023 • Business Wire • 11/14/2023 05:00:00 PM
- Genomic Vision: Financial Information for the Third Quarter of 2023 • Business Wire • 11/14/2023 05:00:00 PM
- Genomic Vision : Nombre total d’actions et de droits de vote • Business Wire • 11/08/2023 05:38:00 PM
- Genomic Vision : communiqué relatif aux démissions au sein de la gouvernance • Business Wire • 11/07/2023 05:00:00 PM
- GV Announces Terminated Mr. Charlie Penn's employment as COO • PR Newswire (US) • 11/06/2023 10:00:00 PM
- GV to Hold Annual Shareholder Meeting on December 11, 2023 • PR Newswire (US) • 11/06/2023 09:30:00 PM
- Genomic Vision sollicite l’ouverture d’une procédure de redressement judiciaire • Business Wire • 11/03/2023 05:00:00 PM
- Genomic Vision Requests Receivership Proceedings • Business Wire • 11/03/2023 05:00:00 PM
- Genomic Vision élargit son offre de services de Replication Combing Assay • Business Wire • 11/02/2023 06:00:00 AM
- Genomic Vision Expands Its Replication Combing Assay Service Offering • Business Wire • 11/02/2023 06:00:00 AM
- Genomic Vision participera au 30ème congrès annuel de la Société Européenne de Thérapie Génique et Cellulaire (ESGCT) à Bruxelles du 25 au 26 octobre 2023 • Business Wire • 10/24/2023 04:00:00 PM
- Genomic Vision at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels from 25 to 26 October 2023 • Business Wire • 10/24/2023 04:00:00 PM
- GV Announces A New Sharing Education Program • PR Newswire (US) • 10/19/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM